These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 23236717)

  • 21. Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom.
    De Cock E; Hutton J; Canney P; Body JJ; Barrett-Lee P; Neary MP; Lewis G
    Clin Ther; 2005 Aug; 27(8):1295-310. PubMed ID: 16199254
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evidence to inform decision makers in Thailand: a cost-effectiveness analysis of screening and treatment strategies for postmenopausal osteoporosis.
    Kingkaew P; Maleewong U; Ngarmukos C; Teerawattananon Y
    Value Health; 2012; 15(1 Suppl):S20-8. PubMed ID: 22265062
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis.
    Bilezikian JP
    Am J Med; 2009 Feb; 122(2 Suppl):S14-21. PubMed ID: 19187808
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potential clinical and economic impact of nonadherence with osteoporosis medications.
    Hiligsmann M; Rabenda V; Gathon HJ; Ethgen O; Reginster JY
    Calcif Tissue Int; 2010 Mar; 86(3):202-10. PubMed ID: 20205345
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in Canada.
    Chau D; Becker DL; Coombes ME; Ioannidis G; Adachi JD; Goeree R
    J Med Econ; 2012; 15 Suppl 1():3-14. PubMed ID: 23035625
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates.
    Earnshaw SR; Graham CN; Ettinger B; Amonkar MM; Lynch NO; Middelhoven H
    Curr Med Res Opin; 2007 Oct; 23(10):2517-29. PubMed ID: 17825128
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Weekly versus monthly drug regimens: 1-year compliance and persistence with bisphosphonate therapy.
    Gold DT; Trinh H; Safi W
    Curr Med Res Opin; 2009 Aug; 25(8):1831-9. PubMed ID: 19530982
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [New development in bisphosphonate treatment. Characteristics and effectiveness of intermittent bisphophonates].
    Okazaki R
    Clin Calcium; 2009 Jan; 19(1):30-6. PubMed ID: 19122262
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of oral bisphosphonates for osteoporosis at different ages and levels of life expectancy.
    Pham AN; Datta SK; Weber TJ; Walter LC; Colón-Emeric CS
    J Am Geriatr Soc; 2011 Sep; 59(9):1642-9. PubMed ID: 21883116
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Economic assessment based on a clinical study of risedronate. Fracture prevention in elderly women with osteoporosis is cost-effective].
    Borgström F; Zethraeus N
    Lakartidningen; 2003 Jan; 100(1-2):36-40. PubMed ID: 12572135
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men.
    Schousboe JT; Taylor BC; Fink HA; Kane RL; Cummings SR; Orwoll ES; Melton LJ; Bauer DC; Ensrud KE
    JAMA; 2007 Aug; 298(6):629-37. PubMed ID: 17684185
    [TBL] [Abstract][Full Text] [Related]  

  • 32. RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction.
    Curtis JR; Westfall AO; Cheng H; Saag KG; Delzell E
    Osteoporos Int; 2009 Jun; 20(6):973-8. PubMed ID: 18946630
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
    Iwamoto J; Takeda T; Sato Y
    Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bisphosphonates. A cornerstone of osteoporosis treatment.
    Mayo Clin Womens Healthsource; 2007 May; 11(5):1-2. PubMed ID: 17476171
    [No Abstract]   [Full Text] [Related]  

  • 35. A review of the cost effectiveness of bisphosphonates in the treatment of post-menopausal osteoporosis in Switzerland.
    Lippuner K; Pollock RF; Smith-Palmer J; Meury T; Valentine WJ
    Appl Health Econ Health Policy; 2011 Nov; 9(6):403-17. PubMed ID: 21910511
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Practical approaches to the osteoporosis treatment--instructions for drug use that draws the effect of the medicine].
    Ijiri S
    Nihon Rinsho; 2005 Nov; 63(11):2059-67. PubMed ID: 16277272
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness strategies to treat osteoporosis in elderly women.
    Pfister AK; Welch CA; Lester MD; Emmett MK; Saville PD; Duerring SA
    South Med J; 2006 Feb; 99(2):123-31. PubMed ID: 16509549
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Osteoporosis drugs in real-world clinical practice: an analysis of persistence.
    Iolascon G; Gimigliano F; Orlando V; Capaldo A; Di Somma C; Menditto E
    Aging Clin Exp Res; 2013 Oct; 25 Suppl 1():S137-41. PubMed ID: 24046038
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Bisphosphonate use and related pharmaceutical issues II].
    Veszelyné Kotan E; Mészáros Á
    Acta Pharm Hung; 2016; 86(1):23-34. PubMed ID: 27295874
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The cost utility of bisphosphonate treatment in established osteoporosis.
    Iglesias CP; Torgerson DJ; Bearne A; Bose U
    QJM; 2002 May; 95(5):305-11. PubMed ID: 11978902
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.